Natural and Induced Tolerance to Hymenoptera Venom: A Single Mechanism?
Ana Navas,
Berta Ruiz-Leon,
Pilar Serrano,
Manuel Martí,
M Luisa Espinazo,
Nadine Blanco,
Juan Molina,
Corona Alonso,
Aurora Jurado,
Carmen Moreno-Aguilar
Affiliations
Ana Navas
UGC Inmunología-Alergología, Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
Berta Ruiz-Leon
UGC Inmunología-Alergología, Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
Pilar Serrano
UGC Inmunología-Alergología, Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
Manuel Martí
Pharmacology Department, Institute of Molecular Pathology Biomarkers, University of Extremadura (UEx), ARADyAL INS Carlos III, 10071 Cáceres, Spain
M Luisa Espinazo
GC01 Inmunología y Alergología Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, ARADyAL INS Carlos III, 14004 Cordoba, Spain
Nadine Blanco
UGC Inmunología-Alergología, Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
Juan Molina
UGC Inmunología-Alergología, Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
Corona Alonso
UGC Inmunología-Alergología, Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
Aurora Jurado
UGC Inmunología-Alergología, Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
Carmen Moreno-Aguilar
UGC Inmunología-Alergología, Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
Inducing tolerance in Hymenoptera-allergic patients, bee venom immunotherapy (BVIT) is a widely accepted method to treat severe allergy to bee stings. In order to increase the existing knowledge on the underlying immunological mechanisms and look for possible biomarkers predictive of efficacy, a group of 20 bee-venom-allergic patients (AG) were thoroughly examined during their first year of BVIT. In addition, the results of treated patients with those of an untreated group of 20 tolerant beekeepers (TG) who had previously shown a firm suppressor-regulatory profile were compared. Tolerance in AG patients was invariably associated with a significant regulatory response characterised by the expansion of Helios− subpopulation and increased IL-10, specific IgG4 (sIgG4), and kynurenine levels. Although specific IgE (sIgE) levels increased transiently, surprisingly, the T helper type 2 (Th2) population and IL-4 levels rose significantly after one year of immunotherapy. Thus, the picture of two parallel phenomena emerges: a tolerogenic response and an allergenic one. Comparing these results with those obtained from the TG, different immunological mechanisms appear to govern natural and acquired tolerance to immunotherapy. Of particular interest, the kynurenine levels and T regulatory (Treg) Helios− population could be proposed as new biomarkers of response to BVIT.